Zhejiang DIAN Diagnostics Co., Ltd. cancelled the acquisition of 55% stake in Zhejiang Meisheng Health Management Co., Ltd. from Guo Wangda, Xia Aihua, Zhang Xiuhua and from 10 other natural persons.
August 02, 2016
Share
Zhejiang DIAN Diagnostics Co., Ltd. (SZSE:300244) entered into an agreement to acquire 55% stake in Zhejiang Meisheng Health Management Co., Ltd. from Guo Wangda, Xia Aihua, Zhang Xiuhua and from 10 other natural persons for CNY 16 million on August 3, 2015. Under the terms of the transaction, Guo Wangda, Xia Aihua, Zhang Xiuhua shall receive CNY 4.95 million, CNY 4.4 million, and CNY 1.65 million, respectively as part of transaction. Zhejiang DIAN Diagnostics is also carrying out a capital increase in amount of CNY 5 million in Zhejiang Meisheng. As a result of transactions, Zhejiang DIAN Diagnostics will hold 55% stake in Zhejiang Meisheng Health Management. Zhejiang Meisheng Health Management recorded total assets of CNY 15.59 million, total liabilities of CNY 0.05 million, and owner’s equity of CNY 15.55 million, as on June 30, 2015. The transaction has been approved by Board of Zhejiang DIAN Diagnostics.
Zhejiang DIAN Diagnostics Co., Ltd. (SZSE:300244) cancelled the acquisition of 55% stake in Zhejiang Meisheng Health Management Co., Ltd. from Guo Wangda, Xia Aihua, Zhang Xiuhua and from 10 other natural persons on August 3, 2016.
Dean Diagnostic Technology Group Co., Ltd. is a company providing integrated solutions for medical diagnosis. The Company's main business involves inspection services, product services, health management, judicial expertise, contract research organization (CRO), cold chain logistics and other fields. The Company's business is mainly oriented to medical and health institutions at all levels, such as various general and specialized hospitals, community health service centers, township (town) health centers, physical examination centers, disease prevention and control centers, etc. The Company's products include Atomic Bomb in the field of liquid phase mass spectrometry, Hydrogen Bomb in the field of nucleic acid mass spectrometry, and Man-Made Satellite in the field of pathological diagnosis products and molecular diagnosis products, and others.
Zhejiang DIAN Diagnostics Co., Ltd. cancelled the acquisition of 55% stake in Zhejiang Meisheng Health Management Co., Ltd. from Guo Wangda, Xia Aihua, Zhang Xiuhua and from 10 other natural persons.
DIAN DIAGNOSTICS GROUP CO.,LTD. 
